PAVmed (PAVM) AI Stock Analysis

• Market Cap: $9.77M
• Dividend Yield: N/A
• Average Volume (3M): 377.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: -99.28%
• EPS Growth: -46.16%
• Country: US
• Employees: 39
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -8.70
• Shares Outstanding: 1,063,150
• 10 Day Avg. Volume: 774,204
• 30 Day Avg. Volume: 377,786
• PEG Ratio: >-0.01
• Price to Book (P/B): -2.43
• Price to Sales (P/S): 2.03
• P/FCF Ratio: -0.18
• Enterprise Value/Market Cap: 1.58
• Enterprise Value/Revenue: 533.35
• Enterprise Value/Gross Profit: -79.73
• Enterprise Value/Ebitda: 9.61
• 1Y Price Target: $17.00
• Price Target Upside: 5762.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $9.00 ▲(3003.45% Upside)

The score is held down primarily by weak financial performance (large ongoing losses and negative operating/free cash flow). Earnings-call updates provide some support via improving strategic momentum (Medicare coverage progress and extended runway), but technicals remain broadly bearish versus longer-term averages and the reverse split event reinforces elevated risk.

Positive Factors

Reimbursement Progress (EsoGuard)

Unanimous Medicare contractor endorsement is a structural positive: formal payer coverage reduces adoption barriers, improves reimbursement predictability and broadens the addressable market for EsoGuard. That supports sustained test volumes and revenue scaling over multiple quarters to years.

Near-term Funding Runway (Lucid)

A near-term $27M capital raise materially extends Lucid’s operational runway through 2026, lowering immediate liquidity and execution risk. This funding supports commercialization, reimbursement activities and clinical operations without urgent dilutive financing, enabling multi-quarter strategic execution.

Commercial Partnerships & Pipeline Expansion

The OSU commercial rollout and licensing activity (including planned FDA submission for an implantable device and endoscopic tech licensing) strengthen clinical validation and distribution channels. Strategic academic partnerships can accelerate adoption and create pipeline-related revenue streams over time.

Negative Factors

Deep Negative Profitability

Consistently negative gross and net margins indicate the business currently cannot cover product and operating costs. Without sustained revenue growth or structural cost reductions, profitability remains out of reach, pressuring long-term return metrics and shareholder value creation.

Negative Operating and Free Cash Flow

Ongoing negative operating and free cash flows mean the company relies on external financing to fund operations. That structural cash burn increases refinancing risk and can force dilution or curtailed investment if capital markets tighten, limiting sustainable growth execution.

Reverse Stock Split / Listing Risk

A 1-for-30 reverse split signals prolonged share-price weakness and listing compliance strain, which can concentrate ownership, deter institutional interest and complicate future equity raises. This reflects underlying governance and market-confidence challenges that can hinder long-term capital access.

PAVmed Business Overview & Revenue Model

Company Description

PAVmed Inc. is a medical technology company focused on the development and commercialization of innovative medical devices and diagnostic tools. Operating primarily in the healthcare sector, PAVmed aims to improve patient outcomes through its core products, which include devices for gastroenterology, urology, and other specialty areas. The company is known for its commitment to addressing unmet medical needs with solutions that enhance clinical workflows and patient care.

How the Company Makes Money

PAVmed generates revenue through the sale of its medical devices and products, which are marketed to hospitals, clinics, and healthcare providers. The company has established key partnerships and collaborations that enhance its product offerings and market reach, contributing to its sales. Additionally, PAVmed's revenue model may include licensing agreements and potential royalties from its innovative technologies. The company also seeks to leverage reimbursements from insurance providers for its products, which can further enhance its revenue streams.

PAVmed Financial Statement Overview

Summary

Financials remain weak: deeply negative margins and persistent losses (income statement score 10) plus negative operating/free cash flow (cash flow score 15). Balance sheet leverage appears more manageable (balance sheet score 20), but negative ROE underscores poor returns and overall financial strain.

Income Statement

PAVmed's income statement reveals significant challenges, with negative profit margins across all metrics. The TTM gross profit margin is deeply negative, indicating costs far exceed revenues. The net profit margin is also substantially negative, reflecting ongoing losses. Despite a positive revenue growth rate, the company's profitability remains a concern due to high operating losses.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio for TTM, suggesting manageable leverage. However, the return on equity is negative, indicating inefficiencies in generating returns on shareholders' investments. The equity ratio is relatively stable, but the negative ROE highlights profitability issues.

Cash Flow

Cash flow analysis indicates negative operating and free cash flows, with a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. The free cash flow to net income ratio is close to 1, suggesting cash flow is aligned with net losses, but overall cash flow health is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.00K	3.00M	2.45M	377.00K	500.00K	0.00
Gross Profit	-194.00K	-3.04M	-3.97M	-3.24M	-85.00K	0.00
EBITDA	1.61M	29.67M	-75.74M	-99.50M	-55.90M	-23.33M
Net Income	3.10M	39.79M	-64.17M	-88.98M	-50.35M	-34.28M
Balance Sheet
Total Assets	38.07M	30.66M	33.12M	53.98M	86.98M	19.78M
Cash, Cash Equivalents and Short-Term Investments	3.10M	1.19M	19.64M	42.75M	79.25M	17.52M
Total Debt	9.28M	31.86M	48.73M	36.64M	0.00	14.96M
Total Liabilities	12.28M	37.69M	57.14M	43.05M	7.56M	20.25M
Stockholders Equity	35.78M	-2.50M	-53.83M	-9.68M	61.67M	1.90M
Cash Flow
Free Cash Flow	-3.58M	-33.61M	-52.28M	-72.53M	-42.06M	-21.97M
Operating Cash Flow	-3.56M	-33.55M	-52.04M	-70.98M	-40.59M	-21.91M
Investing Cash Flow	-21.00K	-16.18M	758.00K	-4.74M	-3.72M	-55.00K
Financing Cash Flow	5.92M	31.28M	31.17M	38.21M	104.31M	33.01M

PAVmed Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAVM, the sentiment is Neutral. The current price of 0.29 is below the 20-day moving average (MA) of 8.10, below the 50-day MA of 9.47, and below the 200-day MA of 15.01, indicating a neutral trend. The MACD of -0.42 indicates Negative momentum. The RSI at 51.10 is Neutral, neither overbought nor oversold. The STOCH value of 83.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PAVM.

PAVmed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNON	49 Neutral	$10.76M	-0.35	-197.26%	―	-2.47%	91.23%
PAVM	47 Neutral	$9.77M	-0.51	20.03%	―	-99.28%	-46.16%
SSKN	46 Neutral	$7.54M	-0.49	-207.19%	―	-5.19%	-0.81%
HSCS	46 Neutral	$10.04M	-0.47	-220.42%	―	-41.03%	35.71%
CODX	44 Neutral	$7.02M	-0.10	-62.12%	―	-87.84%	29.16%
BMRA	38 Underperform	$7.94M	-1.74	-69.61%	―	-11.31%	47.64%

PAVmed Corporate Events

PAVmed Announces Reverse Stock Split to Maintain Nasdaq Listing

On December 30, 2025, PAVmed Inc. announced that it will implement a 1-for-30 reverse stock split of its common stock, effective January 2, 2026, following shareholder approval at a special meeting on December 5, 2025 and board approval of the ratio on December 8, 2025. The move, which also reduces authorized common shares from 250 million to 25 million, is aimed at lifting PAVmed’s share price above Nasdaq’s $1.00 minimum bid requirement after a prolonged period of non-compliance, and will proportionately adjust outstanding options, convertible securities and equity plan share reserves while rounding up any fractional shares to the nearest whole share; the company’s Nasdaq ticker will remain PAVM, though its CUSIP number will change.

The most recent analyst rating on (PAVM) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

PAVmed Approves Reverse Stock Split Amendment

On December 5, 2025, PAVmed Inc. held a special meeting where stockholders approved an amendment to the company’s certificate of incorporation. This amendment allows for a reverse stock split at a ratio between 1-for-10 and 1-for-30, and a reduction in authorized common stock from 250 million to 25 million shares. The board of directors has yet to decide the specific ratio for the reverse split but plans to implement the changes soon by filing with the Delaware Secretary of State.

The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

PAVmed Announces Q3 2025 Financial Results and Updates

On November 13, 2025, PAVmed Inc. announced a business update and financial results for the third quarter of 2025. The company highlighted significant advancements, including Veris Health’s commercial phase launch with The Ohio State University James Cancer Hospital and the relaunch of its implantable physiological monitor development. PAVmed also signed a letter of intent to license a new endoscopic imaging technology from Duke University, aiming to expand its innovation pipeline. Lucid Diagnostics reported $1.2 million in revenue from EsoGuard tests and received unanimous support for Medicare coverage, strengthening its financial position with a public stock offering. The company reported a GAAP net loss of $6.3 million for the quarter, with cash reserves increasing to $3.1 million.

The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.